Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes but is not limited to: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial. Fusion has multiple other pipeline programs that will soon be entering into early FIH trials. In addition, Fusion is pursuing combination programs between RCs and other therapeutic modalities including DNA Damage Response Inhibitors (DDRis) and immune-oncology agents. To support execution for these programs, Fusion has a fully operational Good Manufacturing Practice (GMP) compliant state-of-the-art radioconjugate manufacturing facility to meet supply demand for our growing pipeline of RCs.
The Research Associate II, Biology position will report to the Senior Director, Biology.
Responsibilities:
- Safe handling of radioactive and potentially biohazardous materials;
- Conduct and analyze established in vitro assays such as protein quantification, western blotting, immunohistochemistry (IHC), flow cytometry and in vitro radio and/or fluorescent probe conjugated-antibody binding assays and any related molecular and biochemical assays;
- Maintenance of mammalian cell cultures
- May assist with in vivo studies, such as establishment of mouse models of cancer (subcutaneous xenografts), conduct biodistribution and efficacy studies
- Analyze data and produce high quality and well documented experimental data reports with strong attention to detail;
- Troubleshooting of experimental/procedural roadblocks;
- Development and validation of novel in vitro and in vivo assays to support new therapeutic modalities;
- Work effectively within a cross-functional team of biologists, radiochemists and in vivo pharmacology scientist to support ongoing research studies, to ensure achievement of project milestones;
Qualifications:
- B.Sc. with at least 3-5 years or MSc. with at least 2 years of post-graduate academic or industry experience in Molecular/Cell Biology, Immunology, and/or Biochemistry with required knowledge and skill set
- Knowledge of cell/cancer biology, mammalian cell culture, flow cytometry, western blotting, and other molecular biology techniques
- Experience with the safe handling of radioactive and potentially biohazardous materials is an asset.
- Experience with radiopharmaceutical development, and related assays is considered an asset;
- Experience with rodent models of cancer is considered an asset;
- Ability to work independently and contribute to internal project teams and achieving scientific goals, communication of results, and solving multifaceted scientific challenges;
- Ability to adapt to, perform, and develop unfamiliar methods in a rapidly evolving research environment;
- Excellent verbal and written proficiency in English;
- Ability to work effectively in a multi-disciplinary team and communicate with colleagues at all levels;
- Work effectively under pressure and tight timelines;
- Strong team player and excellent interpersonal skills;
Fusion Pharmaceuticals is an equal opportunity employer that is committed to inclusive, barrier-free recruitment and selection processes, if contacted for an interview, please advise Human Resources if you require accommodation.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.
